Fundacion CENIT para la Investigación en Neurociencias - Clinic
Welcome,         Profile    Billing    Logout  
 0 Trials 
3 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Lerzo, Guillermo
ZEST, NCT04915755 / 2020-003973-23: Efficacy and Safety Comparison of Niraparib to Placebo in Participants With Human Epidermal Growth Factor 2 Negative (HER2-) Breast Cancer Susceptibility Gene Mutation (BRCAmut) or Triple-Negative Breast Cancer (TNBC) With Molecular Disease

Calendar Jan 2025 - Dec 2025: Pivotal data from ZEST trial for HER2-negative BRCA-mutated or triple-negative breast cancer
Active, not recruiting
3
43
Europe, Canada, Japan, US, RoW
Niraparib, Placebo
GlaxoSmithKline
Neoplasms, Breast
06/24
12/25
KEYNOTE-D78, NCT04879329: A Study of Disitamab Vedotin Alone or With Pembrolizumab in Urothelial Cancer That Expresses HER2

Recruiting
2
372
Europe, Canada, Japan, US, RoW
disitamab vedotin, RC48-ADC, pembrolizumab, KEYTRUDA®
Seagen, a wholly owned subsidiary of Pfizer, Merck Sharp & Dohme LLC
Urothelial Carcinoma
12/26
06/28
Mendoza, Carla
NCT05951777: Autologous Adipose Derived Mesenchymal Stem Cells for Chronic Traumatic Brain Injury

Recruiting
2
51
US
Autologous HB-adMSCs, Normal Saline
Hope Biosciences, The University of Texas Health Science Center, Houston
Traumatic Brain Injury
12/26
12/26
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Lerzo, Guillermo
ZEST, NCT04915755 / 2020-003973-23: Efficacy and Safety Comparison of Niraparib to Placebo in Participants With Human Epidermal Growth Factor 2 Negative (HER2-) Breast Cancer Susceptibility Gene Mutation (BRCAmut) or Triple-Negative Breast Cancer (TNBC) With Molecular Disease

Calendar Jan 2025 - Dec 2025: Pivotal data from ZEST trial for HER2-negative BRCA-mutated or triple-negative breast cancer
Active, not recruiting
3
43
Europe, Canada, Japan, US, RoW
Niraparib, Placebo
GlaxoSmithKline
Neoplasms, Breast
06/24
12/25
KEYNOTE-D78, NCT04879329: A Study of Disitamab Vedotin Alone or With Pembrolizumab in Urothelial Cancer That Expresses HER2

Recruiting
2
372
Europe, Canada, Japan, US, RoW
disitamab vedotin, RC48-ADC, pembrolizumab, KEYTRUDA®
Seagen, a wholly owned subsidiary of Pfizer, Merck Sharp & Dohme LLC
Urothelial Carcinoma
12/26
06/28
Mendoza, Carla
NCT05951777: Autologous Adipose Derived Mesenchymal Stem Cells for Chronic Traumatic Brain Injury

Recruiting
2
51
US
Autologous HB-adMSCs, Normal Saline
Hope Biosciences, The University of Texas Health Science Center, Houston
Traumatic Brain Injury
12/26
12/26

Download Options